ClinicalTrials.gg
CompletedNCT06969664Updated Aug 19, 2025

A Trial of SHR7280 in Healthy Subjects

A Phase 1 interventional study of SHR7280 Tablet and SHR7280 Placebo Tablet in Endometriosis, Uterine Fibroids and Assisted Reproduction, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Endometriosis with a site in China — 16 open to participants now, 17 under way, 2 of them phase 3. Endometriosis · China.

Enrollment
26th of 28
16 · median 161
Started
2025
with 7 others
Phase 1
5 of 47
1 open now
Registered
36th of 47
by date
Lead sponsor
4 of 47
Jiangsu HengRui Medicine Co., Ltd.

Among the 47 studies in Endometriosis with a site in China, this one is the 26th largest by enrollment of the 28 interventional ones that give a count, is one of 8 that started in 2025, is one of 5 in phase 1, and was the 36th registered.

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

Browse Endometriosis studies →

Open to participants now

16 of the 47 studies in Endometriosis with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Endometriosis with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the effect of high-fat meal on pharmacokinetics of SHR7280 after oral administration and the effect of SHR7280 on QT interval at low and high doses in healthy Chinese volunteers.

03

Conditions studied

  • Endometriosis
  • Uterine Fibroids
  • Assisted Reproduction
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form prior to any activities in the trail, demonstrate comprehension of the trial procedures and methodology, and agree to strictly adhere to the protocol throughout the study period.
  2. Be aged between 18 and 45 years inclusive (determined at the time of signing the informed consent form).
  3. Have a body weight of ≥50 kg for males and ≥45 kg for females, with a (BMI) between 18 and 26 kg/m² inclusive.
  4. Have no plans for pregnancy or sperm/egg donation from the time of signing the inform consent form until 1 week after the last administration of the product, and agree to use highly effective measures.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with a history of chronic or serious diseases, or current conditions affecting the respiratory, circulatory, digestive, urinary, hematological, endocrine, immune, nervous, or psychiatric systems, and deemed ineligible to participate in this trial by the investigator.
  2. Females who are pregnant, breastfeeding, or with a positive serum pregnancy test during the screening or baseline period.
  3. History of smoking (average daily cigarette consumption >5 cigarettes) within 3 months prior to randomization, or any use of tobacco products during the study period.
  4. History of drug abuse, positive urine drug abuse screen at the screening period.
  5. Receipt of live (attenuated) vaccines within 1 month prior to screening or planned administration during the trial (excluding influenza vaccines).
  6. Undergoing any surgical procedure within 3 months prior to randomization, incomplete recovery from surgery, or anticipated need for surgery or hospitalization during the trial period.
  7. Inability to comply with standardized dietary requirements, intolerance to high-fat meals, or presence of dysphagia.
  8. Any condition judged by the investigator to potentially affect drug absorption, distribution, metabolism, or excretion, reduce compliance, or pose other risks that make participation in the study inappropriate.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Treatment group A

    Drug: SHR7280 Tablet · Drug: SHR7280 Placebo Tablet

  • Experimental
    Treatment group B

    Drug: SHR7280 Tablet · Drug: SHR7280 Placebo Tablet

Interventions

  • Oral SHR7280 tablet.

  • DrugSHR7280 Placebo Tablet

    Oral SHR7280 placebo tablet.

06

What researchers measure

Primary outcomes

  1. Peak concentration (Cmax)

    Time frame: Day 1 to Day 8.

  2. Area under the plasma concentration-time curve from time 0 to the last quantifiable timepoint (AUC0-t)

    Time frame: Day 1 to Day 8.

  3. Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)

    Time frame: Day 1 to Day 8.

Secondary outcomes

  1. Time to peak concentration (Tmax)

    Time frame: Day 1 to Day 8.

  2. Elimination half-life (t1/2)

    Time frame: Day 1 to Day 8.

  3. Adverse events (AEs)

    Time frame: Day 1 to Day 15.

07

Study locations

1 site
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510300, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Jul 2025, 1 month.

Of 24 phase 1 interventional studies under Endometriosis, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 26. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 14, 2025
StartActual
May 19, 2025
Primary completionActual
Jul 5, 2025
CompletionActual
Jul 5, 2025
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06969664
Responsible party
Sponsor
First posted
May 14, 2025
Start date
May 19, 2025
Primary completion
Jul 5, 2025
Completion
Jul 5, 2025
Last update
Aug 19, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GnRH Antagonist SHR7280

Start the discussion